| Literature DB >> 23840462 |
Alessandro Ghezzo1, Paola Visconti, Provvidenza M Abruzzo, Alessandra Bolotta, Carla Ferreri, Giuseppe Gobbi, Gemma Malisardi, Stefano Manfredini, Marina Marini, Laura Nanetti, Emanuela Pipitone, Francesca Raffaelli, Federica Resca, Arianna Vignini, Laura Mazzanti.
Abstract
It has been suggested that oxidative stress may play a role in the pathogenesis of Autism Spectrum Disorders (ASD), but the literature reports somewhat contradictory results. To further investigate the issue, we evaluated a high number of peripheral oxidative stress parameters, and some related issues such as erythrocyte membrane functional features and lipid composition. Twenty-one autistic children (Au) aged 5 to 12 years, were gender and age-matched with 20 typically developing children (TD). Erythrocyte thiobarbituric acid reactive substances, urinary isoprostane and hexanoyl-lysine adduct levels were elevated in Au, thus confirming the occurrence of an imbalance of the redox status of Au, whilst other oxidative stress markers or associated parameters (urinary 8-oxo-dG, plasma radical absorbance capacity and carbonyl groups, erythrocyte superoxide dismutase and catalase activities) were unchanged. A very significant reduction of Na(+)/K(+)-ATPase activity (-66%, p<0.0001), a reduction of erythrocyte membrane fluidity and alteration in erythrocyte fatty acid membrane profile (increase in monounsaturated fatty acids, decrease in EPA and DHA-ω3 with a consequent increase in ω6/ω3 ratio) were found in Au compared to TD, without change in membrane sialic acid content. Some Au clinical features appear to be correlated with these findings; in particular, hyperactivity score appears to be related with some parameters of the lipidomic profile and membrane fluidity. Oxidative stress and erythrocyte membrane alterations may play a role in the pathogenesis of ASD and prompt the development of palliative therapeutic protocols. Moreover, the marked decrease in NKA could be potentially utilized as a peripheral biomarker of ASD.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23840462 PMCID: PMC3686873 DOI: 10.1371/journal.pone.0066418
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and clinical features of the autistic children group.
| No. | Gender | Age (months) | Age of onset (months) | Cognitive/developmental impairment | DSM IV-TRdiagnosis | ADOSscore | ADOSdiagnosis | CARSglobalscore | CARS activity level item score (hyperactivity) | CARS body use item score (stereotypes) |
| 1 | M | 66 | ≤12 | Moderate | PDD | 18 | Au | 40.5 | 2.5 | 3.5 |
| 2 | M | 74 | ≤12 | Severe | PDD | 21 | Au | 42 | 2.5 | 2.5 |
| 3 | M | 64 | ≤12 | Moderate | PDD | 16 | Au | 35 | 2.5 | 2 |
| 4 | M | 103 | 13–18 | Moderate | PDD | 19 | Au | 44.5 | 3 | 3 |
| 5 | M | 61 | ≤12 | Severe | PDD | 21 | Au | 46 | 3.5 | 4 |
| 6 | M | 71 | 13–18 | Severe | PDD | 22 | Au | 41 | 2 | 3 |
| 7 | M | 142 | ≤12 | Severe | PDD | 22 | Au | 44.5 | 2.5 | 3 |
| 8 | M | 131 | 13–18 | Severe | PDD-NOS | 16 | Au | 38 | 3 | 3 |
| 9 | M | 66 | 13–18 | Moderate | PDD | 22 | Au | 40.5 | 3 | 3 |
| 10 | F | 66 | 13–18 | Borderline IQ | PDD-NOS | 15 | Au | 41.5 | 2.5 | 2 |
| 11 | M | 74 | 13–18 | Severe | PDD | 22 | Au | 42.5 | 3 | 2.5 |
| 12 | F | 66 | 13–18 | Severe | PDD | 22 | Au | 43.5 | 3.5 | 3.5 |
| 13 | M | 66 | 13–18 | Mild | PDD-NOS | 14 | Au | 34 | 2 | 2 |
| 14 | M | 89 | 19–24 | Mild | PDD | 19 | Au | 40 | 3 | 3 |
| 15 | M | 102 | 13–18 | Mild | PDD | 22 | Au | 36.5 | 2 | 2.5 |
| 16 | F | 110 | 25–30 | Moderate | PDD | 15 | Au | 47.5 | 3.5 | 3 |
| 17 | M | 79 | 13–18 | Moderate | PDD | 19 | Au | 37 | 2.5 | 3 |
| 18 | M | 144 | 13–18 | Severe | PDD-NOS | 20 | Au | 39 | 3 | 3.5 |
| 19 | M | 80 | ≤12 | Normal IQ | PDD | 19 | Au | 36.5 | 2.5 | 2 |
| 20 | M | 79 | ≤12 | Severe | PDD | 21 | Au | 40.5 | 2.5 | 3 |
| 21 | F | 65 | ≤12 | Mild | PDD-NOS | 17 | Au | 31.5 | 2 | 2 |
PDD: Pervasive Developmental Disorder; PDD-NOS: Pervasive Developmental Disorder-Not Otherwise Specified; Au: Autism.
Summary of published results on fatty acid composition of erythrocyte membrane.
| fatty acid composition of erythrocyte membrane | Patients | |
| Highly unsaturated fatty acids (HUFA) | decreased | One ASD patient |
| Stearic acid (18∶0) | increased | 18 Au children with developmental regression |
| Arachidic acid (24∶0) | increased | |
| Total SFA | increased | |
| Oleic acid (18∶1 n-9) | decreased | |
| Nervonic acid (24∶1) | increased | |
| Total MUFA | decreased | |
| Linoleic acid (18∶2 n-6) | increased | |
| Arachidonic acid (ARA) (20∶4 n-6) | decreased | |
| Docosapentaenoic acid (DPA) (22∶5 n-6) | increased | |
| Docosapentaenoic acid (DPA) (22∶5 n-3) | decreased | |
| Total ω3 | decreased | |
| ARA:EPA ratio (20∶4 n-6/20∶5n-3) | increased | |
| Stearic acid (18∶0) | increased | 11 children with classical autism or Asperger |
| Arachidic acid (24∶0) | increased | |
| Nervonic acid (24∶1) | increased | |
| Docosapentaenoic acid (DPA) (22∶5 n-6) | increased | |
| Docosapentaenoic acid (DPA) (22∶5 n-3) | decreased | |
| Total ω3 | decreased | |
| ARA:EPA ratio (20∶4 n-6/20∶5n-3) | increased | |
| Eicosenoic acid (20∶1n9) | increased | 20 Au children with developmental regression (mean age 3.5 years) |
| Erucic acid (22∶1n9) | increased | |
| total MUFA | increased | |
| α-Linolenic acid (18∶3 n-3) | decreased | 49 Au children (mean age 7.5 years) |
| ARA:EPA ratio (20∶4 n-6/20∶5 n-3) | increased |
ARA, arachidonic acid; EPA, eicosapentaenoic acid; MUFA, monounsaturated fatty acids; PUFA; polyunsaturated fatty acids; SFA, saturated fatty acids.
Erythrocyte membrane features and molecules, oxidative stress markers in urine and plasma, antioxidant enzymes activities in erythrocytes.
| Mean values ± St. Dev | % difference Au vsTD | Statistical significance | ||||
| Au (N = 21) | TD (N = 20) | p values |
| |||
|
| ||||||
| Na+/K+-ATPase° | 2.54±0.58 | 7.39±1.62 |
|
| <0.0001 | |
| TMA-DPH° | 0.27±0.02 | 0.25±0.03 |
|
| 0.0368 | |
| DPH° | 0.27±0.02 | 0.25±0.03 |
|
| 0.0469 | |
| TBARS° | 0.72±0.38 | 0.51±0.37 |
|
| 0.0125 | |
| Sialic Acid° | 6.19±4.36 | 7.63±7.08 | −19% | 0.7248 | 0.7248 | |
|
| ||||||
| 8-Isoprostane° | 3.04±1.50 | 2.07±0.54 |
|
| 0.0278 | |
| HEL* | 0.16±0.09 | 0.11±0.05 |
|
| 0.0760 | |
| 8-Oxo-dG* | 484.80±130.07 | 426.46±163.64 | +14% | 0.2127 | 0.346 | |
|
| ||||||
| Carbonyl Groups* | 0.30±0.08 | 0.27±0.11 | +11% | 0.2509 | 0.3763 | |
| ORAC° | 2.47±0.86 | 2.36±0.94 | +5% | 0.4573 | 0.5487 | |
|
| ||||||
| SOD activity° (Au N = 12) | 26.10±4.02 | 25.49±3.78 | +2% | 0.2960 | 0.3947 | |
| Catalase activity* (Au N = 12) | 29.28±6.34 | 31.25±11.06 | −6% | 0.5783 | 0.6309 | |
Au: Autistic children; TD: typically developing children; p values were calculated with non parametric Wilcoxon-Mann-Whitney test (°) or parametric ANOVA test (*); p<0.05: significant; highly significant; pFDR: Benjamini and Hochberg False Discovery Rate (FDR) corrected p-values.
Erythrocyte membrane Fatty Acid profile.
| Mean values (± St. Dev) | % differencesAu vs TD | Statistical significance | |||
| Au (N = 21) | TD (N = 20) | p values |
| ||
|
| 4.80±1.08 | 5.62±0.67 |
|
| 0.07220 |
|
| 18.03±1.25 | 17.04±0.98 |
|
| 0.07220 |
|
| 1.30±0.16 | 1.20±0.11 |
|
| 0.07329 |
|
| 16.42±1.25 | 15.60±0.94 |
|
| 0.07329 |
|
| 2.38±0.24 | 2.52±0.19 |
|
| 0.07329 |
|
| 0.3±0.08 | 0.24±0.09 |
|
| 0.07329 |
|
| 6.66±1.62 | 5.76±0.67 |
|
| 0.07329 |
|
| 0.43±0.16 | 0.51±0.14 |
|
| 0.10308 |
| Total Polyunsaturated Fatty Acids (PUFA)° | 39.40±1.80 | 40.18±1.74 | −2% | 0.1173 | 0.24763 |
| Trans 18∶1° | 0.11±0.05 | 0.14±0.07 | −21% | 0.1863 | 0.35397 |
| Eicosatrienoic acid omega 6 (20∶3)° | 2.25±0.45 | 2.13±0.34 | +6% | 0.3714 | 0.64151 |
| Stearic acid (18∶0)* | 18.58±1.04 | 18.78±0.88 | −1% | 0.4940 | 0.76378 |
| Total Saturated Fatty Acids (SFA)* | 42.31±1.96 | 42.60±1.53 | −1% | 0.6012 | 0.76738 |
| Linoleic omega 6 (18∶2)° | 12.2±0.96 | 12.66±1.34 | −4% | 0.6012 | 0.76738 |
| Total TRANS° | 0.23±0.08 | 0.24±0.06 | −1% | 0.6180 | 0.76738 |
| Trans-ARA° | 0.12±0.06 | 0.11±0.03 | +9% | 0.6756 | 0.76738 |
| Arachidonic acid omega 6 (20∶4)* | 19.57±1.67 | 19.39±1.13 | +1% | 0.6866 | 0.76738 |
| EFA deficiency° | 0.66±0.07 | 0.67±0.08 | −1% | 0.7961 | 0.84033 |
| Palmitic acid (16∶0) * | 23.73±1.94 | 23.82±1.48 | 0% | 0.8810 | 0.88100 |
Au: Autistic children; TD: typically developing children; ARA, arachidonic acid; DHA, docosahexaenoic acid; EFA, essential fatty acids; EPA, eicosapentaenoic acid; MUFA, monounsaturated fatty acids; PUFA; polyunsaturated fatty acids; SFA, saturated fatty acids; TRANS, transfatty acids; p values were calculated with non parametric Wilcoxon-Mann-Whitney test (°) or parametric ANOVA test (*); p<0.05: significant; highly significant; pFDR: Benjamini and Hochberg False Discovery Rate (FDR) corrected p-values.
Significant correlations of clinical features and biochemical data in Autistic children.
| CARS global scores | CARS activity item (Hyperactivity) | Cognitive/developmental impairment level | Age | |
| Total SFA | NS |
|
| NS |
| SFA/MUFA | NS |
| NS | NS |
| TMA-DPH | NS |
| NS |
|
| Total PUFA |
|
| p = 0.0553; | NS |
| Palmitic acid (16∶0) | NS |
|
| NS |
| Arachidonic acidω6 (20∶4) |
|
|
| NS |
| Total MUFA | NS |
| NS | NS |
| Oleic acid (18∶1) | NS |
| NS | NS |
| 8-isoprostane | NS | NS |
| NS |
Non-parametric correlation (Spearman's rho, r) was used to correlate clinical features (CARS, CARS activity item and Age) and biochemical data in the Autistic children group. Non-parametric ANOVA was used for Cognitive/developmental impairment level. MUFA, monounsaturated fatty acids; PUFA; polyunsaturated fatty acids; SFA, saturated fatty acids. p<0.05: significant; highly significant.
pFDR: Benjamini and Hochberg False Discovery Rate (FDR) corrected p-values.